Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children

Department of Clinical Pharmacy, University Medical Center, 6500 HB Nijmegen, The Netherlands.
Journal of Antimicrobial Chemotherapy (Impact Factor: 5.31). 12/2004; 54(6):1152-4. DOI: 10.1093/jac/dkh490
Source: PubMed


Zidovudine is often administered every 12 h in HIV-infected children, but so far no pharmacokinetic data are available for the administration of this agent every 12 h. We have evaluated the plasma pharmacokinetics of zidovudine administered every 8 h versus every 12 h in HIV-1-infected children.
In HIV-1-infected children who switched from zidovudine every 8 h to every 12 h, a pharmacokinetic curve was recorded both before and after the switch. Zidovudine plasma levels were measured by HPLC. Pharmacokinetic parameters were calculated by non-compartmental methods.
Six HIV-1-infected children [median age (range) 7.8 (2.5-13.4) years] were included. In these patients, geometric mean ratios of AUC(0-24) and C(max) for zidovudine every 12 h versus every 8 h were not significantly different from 1.0.
The plasma pharmacokinetic parameters of zidovudine taken every 8 h and every 12 h were not significantly different and therefore suggest bioequivalence of these two dose frequencies.

Download full-text


Available from: Pieter L.A. Fraaij
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Use of highly active antiretroviral therapy has resulted in significant reductions in HIV-related morbidity and mortality. Current therapeutic approaches target cellular entry, viral transcription, and maturation of newly formed virus. Combination therapy is necessary to provide durable suppression of viral replication and immune reconstitution. A variety of consensus treatment guidelines addressing prophylaxis and treatment of HIV infection and opportunistic infections have been developed to serve as resources for clinicians. A summary of U.S. Department of Health and Human Services Guidelines for Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents and International AIDS Society-USA Panel recommendations for Treatment of Adult HIV infection are presented. Considerations for selection of antiretroviral therapy in special populations (e.g., pregnancy, coinfection with tuberculosis, hepatitis B and C virus) are highlighted. U.S. Public Health Service guidelines for management of occupational exposure to HIV and initiation of postexposure prophylaxis are discussed as well as World Health Organization recommendations for use of antiretroviral therapy in resource-limited settings. The pathophysiology of HIV infection, viral load testing methods, viral dynamics, and classification of antiretrovirals are also briefly reviewed.
    Preview · Article · Feb 2006 · Current Pharmaceutical Design
  • [Show abstract] [Hide abstract]
    ABSTRACT: The recommended dose of lamivudine in children is higher when compared with adults: 4 mg/kg vs approximately 2 mg/kg (150 mg) and administered twice a day. Limited data are available to demonstrate that this increased dose results in adequate exposure to lamivudine in children with human immunodeficiency virus (HIV) infection. Data were selected from children who were using lamivudine for at least 2 weeks before a full pharmacokinetic (PK) study was conducted. Lamivudine PK parameters were significantly related to age. The age of 6 years appeared to be a cutoff for a change in PK parameters of lamivudine, with children <6 years of age (n=17) having a median area under the curve 43% lower and a median peak plasma concentration 47% lower (both P<0.001) than older children (n=34). In conclusion, further investigation of the relationship between decreased lamivudine exposure and treatment outcome and long-term resistance development in younger children with HIV infection is warranted.
    No preview · Article · Apr 2007 · Clinical Pharmacology &#38 Therapeutics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human Immunodeficiency Virus (HIV) infection has become a major public health problem in many countries at the last years. Vertical transmission of HIV infection can take place in utero, during delivery and postnatal. We aim to provide an overview that zidovudine (AZT) has been shown to be an inhibitor of HIV replication. National Institutes of Health announced the findings of the AIDS Clinical Trials Group Study relatively to use of the antiretroviral drug zidovudine as reducing perinatal transmission of HIV. Zidovudine may reduce the risk of vertical transmission both by decreasing maternal viral load, and by inhibiting viral replication in the infant as a post-exposure prophylaxis. Paediatric AIDS is a chronic infection that needs to continue be evaluated clinical, epidemiologic in the impact of paediatric HIV disease.
    Full-text · Article · Mar 2008 · LATIN AMERICAN JOURNAL OF PHARMACY
Show more